当前位置: X-MOL 学术Clin. Infect. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Clinical Infectious Diseases ( IF 8.2 ) Pub Date : 2018-04-27 , DOI: 10.1093/cid/ciy175
Tilly Varughese 1 , Ying Taur 1, 2 , Nina Cohen 3 , M Lia Palomba 2, 4 , Susan K Seo 1, 2 , Tobias M Hohl 1, 2 , Gil Redelman-Sidi 1, 2
Affiliation  

Ibrutinib is a Bruton tyrosine kinase inhibitor that is used for the treatment of lymphoid cancers, including chronic lymphocytic leukemia, Waldenström macroglobulinemia, and mantle cell lymphoma. Several case series have described opportunistic infections among ibrutinib recipients, but the full extent of these infections is unknown. We sought to determine the spectrum of serious infections associated with ibrutinib treatment.

中文翻译:

接受依鲁替尼治疗淋巴癌的患者的严重感染

依鲁替尼是一种Bruton酪氨酸激酶抑制剂,用于治疗淋巴样癌,包括慢性淋巴细胞性白血病,Waldenström巨球蛋白血症和套细胞淋巴瘤。多个病例系列已经描述了依鲁替尼接受者之间的机会性感染,但是这些感染的全部范围尚不清楚。我们试图确定与依鲁替尼治疗相关的严重感染的范围。
更新日期:2018-04-27
down
wechat
bug